Table 1 Baseline Characteristics of Included Studies
Study | Year | Country | Duration | Histology | Sample size (Femal/Male) | Age | Treatment | Sampling time | NLR Cut-off value | Outcome | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|
Bambury et al. [17] | 2013 | USA | 2004-2013 | glioblastoma multiforme | 84 (19/65) | median 58 | S+R+C | pretreatment | 4 | multivariate | 7 |
Han et al. [18] | 2015 | China | 2010-2014 | glioblastoma | 152 (57/95) | mean 50 | NR | pretreatment | 4 | multivariate | 6 |
Auezova et al. [19] | 2016 | Russia | 2009-2012 | gliomas | 178 (85/93) | mean 41 | NR | pretreatment | 4 | univariate | 5 |
S.S.Q. et al. [29] | 2017 | Singapore | NR | glioblastoma | 58 (NR) | NR | NR | perioperative | 2.5 | multivariate | 5 |
Kaya et al. [20] | 2017 | Turkey | 2011-2015 | glioblastoma | 90 (NR) | mean 55 | S+R+C | pretreatment | 5 | multivariate | 5 |
Lopes et al. [21] | 2017 | Portugal | 2005-2013 | glioblastoma multiforme | 140 (42/98) | mean 62 | S+C | pretreatment | 5 | multivariate | 5 |
Matthew et al. [22] | 2017 | Canada | 2004-2010 | glioblastoma | 369 (131/238) | median 55 | S+R+C | postoperative | 7.5 | multivariate | 5 |
Wang et al. [23] | 2017 | China | 2009-2014 | glioblastoma | 166 (70/96) | mean 52 | NR | pretreatment | 4 | multivariate | 5 |
Wiencke et al. [24] | 2017 | USA | NR | glioma (grade II-IV) | 72 (20/52) | median 47 | NR | postoperative | 4 | multivariate | 5 |
Bao et al. [28] | 2018 | China | 2012-2017 | glioma | 219 (95/124) | NR | NR | pretreatment | 2.5 | multivariate | 6 |
Wang et al. [25] | 2018 | China | 2010-2013 | glioma (grade I-IV) | 112 (42/70) | mean 50 | NR | pretreatment | 4 | multivariate | 6 |
Weng et al. [26] | 2018 | China | 2011-2014 | glioblastoma | 105 (52/53) | NR | S+R+C | pretreatment | 4 | multivariate | 5 |
Yersal et al. [27] | 2018 | Turkey | 2012-2017 | glioblastoma | 80 (41/39) | mean 56 | S+R+C | pretreatment | 4 | univariate | 5 |
Hao et al. [31] | 2019 | China | 2012-2017 | glioblastoma multiforme | 187 (71/116) | mean 55 | NR | NR | 4.1 | univariate | 6 |
Yang et al. [30] | 2019 | China | 2008-2012 | glioblastoma multiforme | 128 (57/71) | mean 55 | S+R+C | NR | 2.8 | multivariate | 5 |
Gan et al. [32] | 2019 | China | 2014-2018 | glioma (grade III-IV ) | 135 (46/89) | Mean70 | S+R+C | pretreatment | 3 | multivariate | 5 |